http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103215216-B
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_01d74e1f4b646c6f83d40ae812413f8f |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-19 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C40B40-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-63 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C40B50-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 |
| filingDate | 2013-04-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_44c4832f7b10006811f12989dddaa516 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_40d2e0fbc144cb7491139bd9a37f1679 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c3b4a69561870e75662111de203df77a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a55e7a82b86e8d6b97a9a607ded8c7af http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8ca151f80a6f69189fafb13479f5ee61 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dd5bbdcdff35cdf16052924772ed6bda http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fdd6728a1eea5dfeda1263bda5c21ba3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4dc264c8bae7d32ce530fe612dd1e88a |
| publicationDate | 2015-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-103215216-B |
| titleOfInvention | Melanoma therapeutic plasmid DNA (deoxyribonucleic acid) vaccine pSVK-CAVA preparation method as well as dedicated engineering bacterium and fermentation culture medium thereof |
| abstract | The invention discloses a melanoma therapeutic plasmid DNA (deoxyribonucleic acid) vaccine pSVK-CAVA preparation method and a dedicated engineering bacterium and a fermentation culture medium thereof. The engineering bacterium is Escherichia coli XL10-Gold which contains converted melanoma therapeutic plasmid DNA pSVK-CAVA and is named as E.coli XL10-Gold/CAVA. Each 1L of high-yield fermentation culture medium comprises: 12g of casein peptone, 16.61g of yeast extract, 3.05mL of glycerol, 1g of NH4Cl, 100mL of mixed solution of 0.17mol/L of KH2PO4 and 0.72mol/L of K2HPO4, 0.185g of MgSO4, and 1mL of trace elements. The engineering bacterium is high in stability, can be subjected to continuous passage for more than 30 times, can meet the demand of plasmid DNA vaccine pSVK-CAVA pilot test process, the plasmid volume yield obtained after fermentation of the high-yield culture medium is high, and the engineering bacterium can be used for fermentation production of the melanoma therapeutic plasmid DNA vaccine pSVK-CAVA. |
| priorityDate | 2013-04-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 43.